Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment

1. Klareskog, L., Catrina, A. I. & Paget, S. Rheumatoid arthritis. Lancet 373(9664), 659–672 (2009).

2. Radner, H., Smolen, J. S. & Aletaha, D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology 50(2), 381–388 (2011).

3. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79(6), 685–699 (2020).

4. Harre, U. & Schett, G. Cellular and molecular pathways of structural damage in rheumatoid arthritis. Semin. Immunopathol. 39(4), 355–363 (2017).

5. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76(6), 960–977 (2017).

6. Walsh, N. C., Crotti, T. N., Goldring, S. R. & Gravallese, E. M. Rheumatic diseases: The effects of inflammation on bone. Immunol. Rev. 208, 228–251 (2005).

7. Dasgupta, B., Corkill, M., Kirkham, B., Gibson, T. & Panayi, G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J. Rheumatol. 19(1), 22–25 (1992).

8. Kotake, S. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11(1), 88–95 (1996).

9. Ozaki, K. et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat. Genet. 32(4), 650–654 (2002).

10. Nishimoto, N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66(9), 1162–1167 (2007).

11. Teitsma, X. M. et al. Radiographic joint damage in early rheumatoid arthritis patients: Comparing tocilizumab- and methotrexate- based treat-to-target strategies. Rheumatology 57(2), 309–317 (2018).

12. Genovese, M. C. et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients With rheumatoid arthritis and an inadequate response to methotrexate. Arthr. Rheumatol. 68(12), 2857–2866 (2016).

13. Nam, J. L. et al. Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 76(6), 1113–1136 (2017).

14. Hashimoto, J. et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: Data from the SAMURAI study. Mod. Rheumatol. 21(1), 10–15 (2011).

15. van der Heijde, D. et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthr. Rheum. 56(12), 3928–3939 (2007).

16. van der Heijde, D. et al. Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. RMD Open 5(1), e000898 (2019).

17. Butler, D. M., Maini, R. N., Feldmann, M. & Brennan, F. M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw. 6(4), 225–230 (1995).

18. Haworth, C. et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-alpha. Eur. J. Immunol. 21(10), 2575–2579 (1991).

19. Chin, J. E., Winterrowd, G. E., Krzesicki, R. F. & Sanders, M. E. Role of cytokines in inflammatory synovitis. The coordinate regula- tion of intercellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fibroblasts. Arthr. Rheum. 33(12), 1776–1786 (1990).

20. Choy, E. H. & Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344(12), 907–916 (2001).

21. Bazzoni, F. & Beutler, B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334(26), 1717–1725 (1996).

22. Best, J. H., Vlad, S. C., Tominna, L. & Abbass, I. Real-world persistence with tocilizumab compared to other subcutaneous biologic disease-modifying antirheumatic drugs among patients with rheumatoid arthritis switching from another biologic. Rheumatol. Ther. 7(2), 345–355 (2020).

23. Kilcher, G. et al. Rheumatoid arthritis patients treated in trial and real world settings: Comparison of randomized trials with registries. Rheumatology 57(2), 354–369 (2018).

24. Arnett, F. C. et al. The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr. Rheum. 31(3), 315–324 (1988).

25. Pincus, T., Summey, J. A., Soraci, S. A. Jr., Wallston, K. A. & Hummon, N. P. Assessment of patient satisfaction in activities of daily living using a modified stanford health assessment questionnaire. Arthr. Rheum. 26(11), 1346–1353 (1983).

26. Felson, D. T. et al. American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthr. Rheum. 63(3), 573–586 (2011).

27. Sharp, J. T. et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?. Arthr. Rheum. 28(12), 1326–1335 (1985).

28. van der Heijde, D. How to read radiographs according to the Sharp/van der heijde method. J. Rheumatol. 27(1), 261–263 (2000).

29. Bruynesteyn, K., Boers, M., Kostense, P., van der Linden, S. & van der Heijde, D. Deciding on progression of joint damage in paired films of individual patients: Smallest detectable difference or change. Ann. Rheum. Dis. 64(2), 179–182 (2005).

30. Rosenbaum, P. R. & Rubin, D. B. The central role of the propensity score in observational studies for causal effects. Biometrika 70(1), 41–55 (1983).

31. Gravallese, E. M. et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152(4), 943–951 (1998).

32. Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289(5484), 1504–1508 (2000).

33. Dai, J. et al. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. J. Clin. Invest. 106(7), 887–895 (2000).

34. Wong, P. K. et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthr. Rheum. 54(1), 158–168 (2006).

35. Liu, X. H., Kirschenbaum, A., Yao, S. & Levine, A. C. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa} B (RANK) ligand/RANK system. Endocrinology 146(4), 1991–1998 (2005).

36. Kudo, O. et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32(1), 1–7 (2003).

37. Axmann, R. et al. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthr. Rheum. 60(9), 2747–2756 (2009).

38. Lam, J. et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106(12), 1481–1488 (2000).

39. Quinn, J. M., Horwood, N. J., Elliott, J., Gillespie, M. T. & Martin, T. J. Fibroblastic stromal cells express receptor activator of NF- kappa B ligand and support osteoclast differentiation. J. Bone Miner. Res. 15(8), 1459–1466 (2000).

40. Visser, K. et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann. Rheum. Dis. 69(7), 1333–1337 (2010).

41. Vastesaeger, N., Xu, S., Aletaha, D., St Clair, E. W. & Smolen, J. S. A pilot risk model for the prediction of rapid radiographic pro- gression in rheumatoid arthritis. Rheumatology 48(9), 1114–1121 (2009).

42. Legrand, J., Kirchgesner, T., Sokolova, T., Vande Berg, B. & Durez, P. Early clinical response and long-term radiographic progres- sion in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment target. Jt. Bone Spine 86(5), 594–599 (2019).

43. Welsing, P. M. J. et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysis. Arthr. Rheum. 50(7), 2082–2093 (2004).